申联生物(688098) - 2024 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2024 was CNY 121,926,877.95, an increase of 4.79% year-over-year[2] - Net profit attributable to shareholders decreased by 25.04% to CNY 20,383,291.92 in Q3 2024[2] - The net profit attributable to shareholders for the year-to-date period decreased by 138.05% to CNY -14,124,681.40[6] - Total operating revenue for the first three quarters of 2024 reached ¥248,302,819.25, an increase from ¥239,426,012.53 in the same period of 2023, representing a growth of approximately 3.65%[15] - The net profit for the first three quarters of 2024 was a loss of ¥17,020,443.48, compared to a profit of ¥36,484,405.67 in the same period of 2023[16] - The operating profit for the first three quarters of 2024 was a loss of ¥18,962,951.36, down from a profit of ¥43,195,061.03 in 2023[16] Research and Development - R&D investment totaled CNY 16,167,081.47, representing 13.26% of revenue, an increase of 1.29 percentage points year-over-year[3] - Research and development expenses increased to ¥37,754,809.62 from ¥30,259,274.15, reflecting a growth of approximately 24.8%[15] - The company is advancing its mRNA product development and production line construction, with progress in new vaccine projects such as virus-like particle vaccines[8] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,582,011,409.68, a decrease of 0.75% from the previous year[3] - The company's total assets amount to 1,582,011,409.68 RMB, a slight decrease from 1,593,994,285.77 RMB in the previous period[12] - Total liabilities increased to ¥106,336,418.34 from ¥86,926,310.95, indicating a growth of approximately 22.2%[15] - Total equity decreased to ¥1,475,674,991.34 from ¥1,507,067,974.82, a decline of about 2.09%[15] Cash Flow - The company reported a net cash flow from operating activities of CNY 12,473,617.62 year-to-date[2] - The net cash flow from operating activities for the first three quarters of 2024 was 12,473,617.62, a significant improvement from -54,675,362.33 in the same period of 2023[19] - Cash inflow from investment activities totaled 811,780,345.26, down from 1,149,584,784.08 in the previous year[19] - The net cash flow from investment activities was 55,671,682.19, compared to 74,107,977.58 in the prior year[19] - The net increase in cash and cash equivalents at the end of the period was 98,046,790.72, up from 38,876,146.49 in the previous year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,288[9] - The largest shareholder, Yang Yufang, holds 90,063,197 shares, representing 21.93% of the total shares[10] - The company has a total of 43,199,898 shares held by the foreign entity UNITED BIOMEDICAL, INC., accounting for 10.52% of the total shares[10] Operating Costs and Expenses - Total operating costs increased to ¥259,262,501.74 from ¥198,576,174.34, marking a rise of about 30.54%[15] - The company reported a significant increase in sales expenses, which rose to ¥77,225,498.63 from ¥60,578,131.36, an increase of approximately 27.5%[15] - Cash outflow for dividend distribution and interest payments was 14,338,485.84, down from 32,773,668.59 in 2023[19]